PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21210565-4	2004	Because of its specific presence on non-Hodgkin lymphoma tumor cells, the antigen is a therapeutic target of different anti-CD20 Abs, such as rituximab for monotherapy or combination therapy with a chemotherapeutic agent, or tositumomab ((131)I-labeled) or ibritumomab ((90)Y-conjugated) for radioimmunotherapy (RIT), all of which are approved by the United States Food and Drug Administration for the treatment of this disease (4).	ibritumomab tiuxetan	257-268	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	124-128	
16367911-0	2005	Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.	ibritumomab tiuxetan	89-109	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	49-53	
14710396-8	2003	This is a conjugate of an anti-CD20 mAb (ibritumomab, the murine parent of rituximab) with the beta-emitter radionuclide (90)Y.	ibritumomab tiuxetan	41-52	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	31-35